Shah Syed Muhammad Hassan, Ullah Farhat, Khan Shahzeb, Shah Syed Muhammad Mukarram, Isreb Mohamad
Department of Pharmacy, Sarhad University of Science and Information Technology, Peshawar, Pakistan.
Department of Pharmacy, University of Malakand, Chakdara, Dir Lower, Pakistan.
Afr J Tradit Complement Altern Med. 2016 Nov 23;14(1):251-262. doi: 10.21010/ajtcam.v14i1.27. eCollection 2017.
Nanocrystals have the potential to substantially increase dissolution rate, solubility with subsequent enhanced bioavailability via the oral route of a range of poor water soluble drugs. Regardless of other issues, scale up of the batch size is the main issue associated with bottom up approach.
Smart nanocrystals of artemisinin (ARM) was produced relatively at large batch sizes (100, 200, 300 and 400ml) compared to our previously reported study by (Shah, et al., 2016). ARM nanosuspensions/nanocrystals were characterised using zeta sizer, SEM, TEM, DSC, PXRD and RP-HPLC. The nanosuspensions were finally subjected to antimalarial and antimicrobial activity.
The average particle size (PS) for 400 ml batches was 126.5 ±1.02 nm, and the polydispersity index (PI) was 0.194 ± 0.04. The saturation solubility of the ARM nanocrystals was substantially increased to (725.4± 2.0 μg/ml) compared to the raw ARM in water 177.4± 1.3 μg/ml and stabilizer solution (385.3± 2.0 μg/ml). The IC50 value of ARM nanosuspension against . vivax was 65 and 21 folds lower than micronized 19.5 ng/mL and unprocessed drug (6.4 ng/mL) respectively. The ARM nanosuspension was found highly effective compared to unprocessed drug against all the tested microorganism except , and .
The simple precipitation-ultrasonication approach was efficiently employed for fabrication of ARM nanosuspension to scale up the batch size. Similarly, the solubility, antimalarial potential and antimicrobial efficacy of ARM in the form of nanosuspension were significantly enhanced. Findings from this study can persuade research interest for further comprehensive studies using animals model.
纳米晶体有可能大幅提高一系列水溶性差的药物的溶解速率、溶解度,进而通过口服途径提高生物利用度。不管其他问题如何,放大批次规模是与自下而上方法相关的主要问题。
与我们之前(Shah等人,2016年)报道的研究相比,青蒿素(ARM)的智能纳米晶体是以相对较大的批次规模(100、200、300和400毫升)生产的。使用zeta粒度分析仪、扫描电子显微镜(SEM)、透射电子显微镜(TEM)、差示扫描量热法(DSC)、粉末X射线衍射(PXRD)和反相高效液相色谱(RP-HPLC)对ARM纳米混悬液/纳米晶体进行了表征。最终对纳米混悬液进行了抗疟疾和抗菌活性测试。
400毫升批次的平均粒径(PS)为126.5±1.02纳米,多分散指数(PI)为0.194±0.04。与水中的原料药ARM(177.4±1.3微克/毫升)和稳定剂溶液(385.3±2.0微克/毫升)相比,ARM纳米晶体的饱和溶解度大幅提高至(725.4±2.0微克/毫升)。ARM纳米混悬液对间日疟原虫的半数抑制浓度(IC50)值分别比微粉化药物(19.5纳克/毫升)和未加工药物(6.4纳克/毫升)低65倍和21倍。与未加工药物相比,发现ARM纳米混悬液对除[此处原文缺失部分微生物名称]之外的所有测试微生物都非常有效。
简单的沉淀-超声处理方法被有效地用于制备ARM纳米混悬液以扩大批次规模。同样,纳米混悬液形式的ARM的溶解度、抗疟疾潜力和抗菌功效也显著提高。本研究结果可激发使用动物模型进行进一步全面研究的研究兴趣。